Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
The objective is to investigate the efficacy and safety of Envafolimab combined with chemotherapy in the treatment of metastatic or recurrent gastric adenocarcinoma.
Metastatic or Recurrent Gastric Adenocarcinoma
DRUG: Envafolimab|DRUG: Oxaliplatin|DRUG: S1
ORR, Objective response rate, 6 months
PFS, Progression Free Survival, 6 months|OS, Overall Survival, 12 months|DCR, Disease Control Rate, 9 months|DOR, Duration of Response, 12 months|AEs, Percentage of participants experiencing grade 3-5 adverse events, 12 months|Qualify of Life, Based on Quality of Life Questionnare-Core 30, evaluate the quality of life of patients, 12 months
Envafolimab indication: Envafolimab is the world's first subcutaneous injection of PD-L1 monoclonal antibody.Suitable for adult patients with advanced solid tumors with unresectable or metastatic microsatellite highly unstable (MSI-H) or mismatch repair gene defects (dMMR).